A.K. Erdiakov – Ph.D. (Biol.), Senior Research Scientist, Interfaculty Research Laboratory of Adaptation Medicine, Faculty of Fundamental Medicine, Lomonosov Moscow State University
M.V. Tikhonovich – Ph.D. (Med.), Ophthalmologist, Hospital of the Presidential Property Management Department of the Russian Federation
E.M. Klochikhina – Post-graduate Student, Department of Physiology and General Pathology, Faculty of Fundamental Medicine, Lomonosov Moscow State University
O. Budarina – Student, Faculty of Fundamental Medicine, Lomonosov Moscow State University
S.A. Gavrilova – Ph.D. (Biol.), Associate Professor, Department of Physiology and General Pathology, Faculty of Fundamental Medicine, Lomonosov Moscow State University
Proliferative vitreoretinopathy (PVR) is a disease of the retina that can be seen as a healing reaction to the retinal damage. PVR is linked to activation of inflammation and development of fibrous membranes. It has previously been shown that intravitreal injection of the enzyme dispase (D) or lectin concanavalin A (ConA) leads to the development of the intraocular inflammation and PVR in rats and is accompanied by remodelling of the retina. One of the key morphological and histo-logical characteristics of retinal remodeling is the presence of nuclei in its non-nuclear layers. This phenomenon is called migration, and it illustrates the movement of retinal cells, or their nuclei. The present study aimed to systematically investigate migration of nuclei/cells at different stages of development of PVR, the impact of ischemia on the process of migration and the influence of anti-inflammatory therapy on the phenomenon of migration.
In total, 230 normal adult male albino rats (350 ± 50 g) were enrolled in this experiment. A PVR rat models were established by an intravitreal injection either of 2μl of dispase (0.015 U/μl) or of 2μl of concanavalin A solution (ConA) (0.25mg/ml) into the right eye under sterile conditions. 20 minutes later, an intraocular injection either of 2 μl of lornoxicam (8 mg/ml) or 2 μl of triamcinolone (40 mg/ml) was administered. On the 2nd and 3rd days after the initial injection of dispase or of concanavalin A, appropriate drugs were administered systemically. Lornoxicam was delivered intraperitoneally at a dose of 230 mg/kg, while triamcinolone was administered intramuscularly at a dose of 571 mg/kg. A rat model of irreversible retinal ischemia was induced by occlusion of a. carotis interna. Two ligatures were applied to a. carotis interna on anaesthesised animals (directly above the bifurcation of the carotid artery).
The obtained results confirmed the significance of the prostaglandins, components of arachidonic acid metabolism, in the regulation of the retinal cell activity demonstrating perspectives of using inhibitors of cyclooxygenases as a method of prevention and treatment of PVR. The ischemic component of the inflammatory reaction is not the main factor in the activation of migration processes in the retina. Retinoprotective properties of lornoxicam can be a potential prophylaxis for proliferative vitreoretinopathy, as well as a therapeutic agent in ischemic retinal diseases.
- Pastor J.C., de la Rúa E.R., Martín F. Proliferative vitreoretinopathy: Risk factors and pathobiology // Prog. Retin. Eye. Res. 2002. V. 21. № 1. P. 127–144.
- Tixonovich M.V., Iojleva E.E'., Gavrilova S.A. Rol' vospaleniya v razvitii proliferativnoj vitreoretinopatii // Klinicheskaya mediczina. 2015. T. 93. № 7. S. 14–20.
- Moysidis S.N., Thanos A., Vavvas D.G. Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside // Mediators Inflamm. 2012. V. 2012. Article ID 815937, doi:10.1155/2012/815937
- Bonnet M., Guenoun S. Surgical risk factors for severe postoperative proliferative vitreoretinopathy (PVR) in retinal detachment with grade B PVR // Graefes Arch. Clin. Exp. Ophthalmol. 1995. V. 233. № 12. P. 789–791.
- Kon C., Asaria R., Occleston N., Khaw P., Aylward G. Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study // Br. J. Ophthalmol. 2000. V. 84. № 5. P. 506–511.
- Erdyakov A.K., Tixonovich M.V., Rzhavina E.M., Gavrilova S.A. Xarakteristiki setchatki pri razvitii proliferativnoj vitreoretinopatii u kry's posle vnutriglaznoj in''ekczii konkanavalina A i dispazy' // Rossijskij fiziologicheskij zhurnal. 2015. T. 101. № 5. S. 572–585.
- Dement'eva A.A., Kibitov A.A., Erdyakov A.K., Balaczkij A.V., Gavrilova S.A. Vliyanie ingibirovaniya metabolicheskogo kaskada araxidonovoj kisloty' na posleduyushhij profil' e'kspressii cziklooksigenaz i prostaglandinsintaz v glazu kry'sy' v konkanavalinovoj modeli vospaleniya // Texnologii zhivy'x sistem. 2016. T. 13. № 6. S. 14–23.
- Tikhonovich M.V., Erdiakov A.K., Gavrilova S.A. Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one // Int. Ophthalmol. 2017. doi:10.1007/s10792-017-0594-3.
- Lewis G.P., Chapin E.A., Luna G., Linberg K.A., Fisher S.K. The fate of Müller's glia following experimental retinal detachment: nuclear migration, cell division, and subretinal glial scar formation // Mol. Vis. 2010. V. 16. P. 1361–1372.
- Tackenberg M.A., Tucker B.A., Swift J.S., Jiang C., Redenti S., Greenberg K.P., Flannery J.G., Reichenbach A., Young M.J. Müller cell activation, proliferation and migration following laser injury // Mol. vis. 2009. V. 15. P. 1886–1896.
- Matsumura T., Yamanaka T., Hashizume S., Irie Y., Nitta K. Tissue dispersion, cell harvest and fluid suspension culture by the use of bacterial neutral protease // Jpn. J. Exp. Med. 1975. V. 45. № 5. P. 377–382.
- El Ghrably I., Powe D.G., Orr G., Fischer D., McIntosh R., Dua H.S., Tighe P.J. Apoptosis in proliferative vitreoretinopathy // Invest. Ophthalmol. Vis. Sci. 2004 V. 45. № 5. P. 1473–1479.
- Chennamaneni S.R., Bohner A., Bernhisel A., Ambati B.K. Pharmacokinetics and efficacy of Bioerodible Dexamethasone implant in Concanavalin A-induced uveitic cataract model // Pharm. Res. 2014. V. 31. P. 3179–3190.
- Kapin M.A., Yanni J.M., Brady M.T., McDonough T.J., Flanagan J.G., Rawji M.H., Dahlin D.C., Sanders M.E., Gamache D.A. Inflammation mediated retinal edema in the rabbit is inhibited by topical nepafenac // Inflammation. 2003. V. 27. № 5. P. 281–291.